CYTH Cyclo Therapeutics
Cyclo Therapeutics Inc. (“we” “our” “us” or “the Company”) was organized as a Florida corporation on August 9, 1990, with operations beginning in July 1992. In conjunction with a restructuring in 2000, we changed our name from Cyclodextrin Technologies Development Inc. to CTD Holdings Inc. We changed our name to Cyclo Therapeutics Inc. in September 2019 to better reflect our current business.
Company profile
Ticker
CYTH, CTDH, CYTHW
Exchange
Website
CEO
Nathan Scott Fine
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CTD HOLDINGS INC, CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
SEC CIK
Corporate docs
IRS number
593029743
CYTH stock data
()
Press releases
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
25 Mar 21
Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
15 Mar 21
Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
12 Mar 21
Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
10 Mar 21
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
9 Mar 21
Investment data
Securities sold
Number of investors
Calendar
12 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 12.85M | 12.85M | 12.85M | 12.85M | 12.85M | 12.85M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 893.82K | 746.78K | 1.02M | 711.68K |
| Cash used (since last report) | n/a | n/a | 3.07M | 2.57M | 3.51M | 2.45M |
| Cash remaining | n/a | n/a | 9.78M | 10.28M | 9.34M | 10.4M |
| Runway (months of cash) | n/a | n/a | 10.9 | 13.8 | 9.2 | 14.6 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Apr 21 | Ostronic Francis Patrick | Common Stock | Buy | Aquire P | No | No | 7 | 5,000 | 35K | 66,559 |
| 29 Mar 21 | Hrynkow Sharon Hemond | Common Stock | Buy | Aquire P | No | No | 7.46 | 1,000 | 7.46K | 18,350 |
| 29 Mar 21 | Ostronic Francis Patrick | Common Stock | Buy | Aquire P | No | No | 7.6 | 2,000 | 15.2K | 61,559 |
| 29 Mar 21 | Ostronic Francis Patrick | Common Stock | Buy | Aquire P | No | No | 7.4 | 1,000 | 7.4K | 59,559 |
| 29 Mar 21 | Tate Jeffrey | Common Stock | Buy | Aquire P | No | No | 7.5 | 2,000 | 15K | 27,160 |
| 29 Mar 21 | Sieger Markus | Common Stock | Buy | Aquire P | No | No | 8.1 | 10,000 | 81K | 67,614 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
16.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 10 |
| Opened positions | 10 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 2.58M |
| Total shares | 1.01M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Hirschman Orin | 418K | $0 |
| AIGH Capital Management | 350K | $1.52M |
| Armistice Capital | 100K | $435K |
| Worth Venture Partners | 88.69K | $386K |
| Jane Street | 27.89K | $121K |
| Susquehanna International | 15.66K | $68K |
| GS Goldman Sachs | 10.28K | $45K |
| RY Royal Bank Of Canada | 746 | $3K |
| Captrust Financial Advisors | 100 | $0 |
| MS Morgan Stanley | 90 | $0 |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abandon, abnormal, abnormally, absence, absorption, abuse, ACA, acknowledgment, Actelion, adequacy, adult, adulterated, adulthood, affirmed, aggressive, Aid, alleged, alleging, alter, altogether, ambulation, amyloid, animal, APP, apparent, appetite, Arimoclomal, Asia, assert, asserting, ataxia, attention, attestation, attorney, attract, auditory, Australia, automated, autosomal, aware, baseline, BBVA, behavior, behavioral, billion, biochemical, birth, block, blood, bound, brainstem, branded, breach, breadth, breakthrough, broadening, broader, brought, budget, California, called, Canada, capable, case, cataplexy, cell, Century, CFO, cGMP, challenge, challenged, challenging, chart, choice, choose, Circuit, circumvent, clearance, cleavage, Clinician, CMS, cognition, cognitive, commerce, compartment, competitor, compromise, conclusion, conclusive, Concurrent, conditionally, confidential, confidentiality, Congressional, constituent, constitutionality, contend, context, contingent, contrary, contrast, convey, Cooperation, copy, correct, corridor, country, creation, CSF, curtailment, cybersecurity, CYTH, CYTHW, decide, decision, defend, defending, deferral, delisted, dementia, demonstrate, demonstrated, demonstrating, denial, denied, Denmark, denying, deployment, Description, devote, Diana, diarrhea, difficulty, diminished, disability, disagree, discover, disgorgement, dispersed, disproportionate, dissemination, dissuade, divert, DOJ, domain, dosage, dropping, duration, dystonia, earlier, educate, Education, electrical, elevated, EMA, encourage, endpoint, energy, enforce, enforceability, Enforcement, engineering, enlargement, epileptic, equivalent, essential, ethical, EU, evolving, exact, excretion, exhibit, exhibited, expedite, Expedited, eye, factual, faulty, FDCA, fill, fillipin, fire, flexibility, Fordham, forgiven, formula, found, gap, Gaucher, GCP, gelastic, gene, geriatric, goal, half, healthy, hearing, hereof, HIPAA, HITECH, home, hyperreflexia, illegally, Impression, imprisonment, improper, inability, inappropriate, incentivize, incidence, inclusion, inconsistent, incontinence, increasingly, indemnification, indemnify, indirectly, induce, infancy, inflammation, infringe, infringed, infringement, infringing, infusion, injunctive, insomnia, intensity, intentional, interfere, interpreted, interstate, interstitial, intervention, IntraBio, introduced, invalid, invalidate, invalidated, IRB, irreversible, journal, judgement, kind, knowingly, landlord, language, latency, lengthy, letter, literature, live, local, lumbar, lysosomal, lysosome, malware, marker, marketplace, Maxim, maximum, maze, MD, meaningful, Medicaid, Medicare, medicine, melatonin, Mental, miglustat, Mini, misappropriation, misbranded, misconduct, misdiagnosed, moiety, morbidity, mortality, mother, motor, mouse, movement, mutated, narcolepsy, narrowly, Nasdaq, nausea, NDA, necessitate, negligent, neurocognitive, neurodegeneration, neurodegenerative, neurofibrillary, neuroprotective, Nevada, NME, nondeductible, notification, notified, onset, optimal, optimize, Orphazyme, outline, outweigh, overlap, oversee, overseeing, pair, panel, Parkinson, partial, partially, passed, passing, pathway, Paycheck, payor, PDUFA, pediatric, PEO, peripheral, permission, pharmacy, physical, PIP, pivotal, Portability, potency, preclinical, precursor, predictor, preliminarily, prescription, preserve, presidential, pressure, prevail, prevalence, priority, privacy, proceed, profile, properly, prosecuting, protein, provoke, psychiatric, put, qualification, qualitative, quotation, rarity, reached, reauthorized, rebate, receipt, recessive, recommendation, recommending, Reconciliation, reconsider, recordkeeping, recruitment, recycle, redesign, referral, reform, regenerative, reincorporated, reject, relaxing, released, relief, remedy, remotely, remuneration, repeal, replicate, reproduce, requisite, resolution, resolve, restitution, restoration, restore, restraining, restrict, restricted, resubmitted, revocation, reward, robust, rolled, rolling, saccadic, sample, sampled, satisfaction, scale, score, scored, secret, sequential, shelf, shorten, shortened, show, showed, showing, Similarly, sleep, slower, slowly, social, solicitation, sophistication, speaking, speculative, speech, staining, statistically, stemming, stop, store, strength, strictly, strong, struck, subcutaneously, submission, subpopulation, substance, substantive, superior, Supreme, surrogate, surveillance, survival, susceptible, suspend, suspension, swallow, swallowing, Symptomatic, tau, telecommunication, territory, terrorism, Theindependent, therapeutic, therapist, therapy, ThinkEquity, thrombocytopenia, timeline, tolerability, tolerance, tolerated, trafficking, trait, transmit, transparency, trapped, Treaty, true, trued, Trump, turn, unacceptable, unannounced, unapproved, unchallenged, undergo, undergoing, Underwriter, underwriting, unenforceable, unforeseen, uniformly, unintentionally, unmanaged, unmet, unpatented, unreasonable, untitled, upheld, usage, variety, verify, version, viability, viable, violate, visualized, voluntarily, voucher, vulnerable, waive, waived, waiver, walking, willfully, win, withdrew, worsen, writing, Zavesca, Zealand
Removed:
accountant, acquired, acted, additive, advance, advisor, affiliated, alcohol, ameliorative, American, analyst, anticipation, appointed, appointment, attending, automatic, banking, bear, began, behalf, Benson, biosimilar, book, Botany, bought, Box, building, built, calculated, caption, career, carryback, ceased, CEDC, CEO, Chairman, Chicago, chosen, cited, classification, Coast, compensate, competitively, composed, comprised, computing, conflict, Consiglio, constant, Consultant, consummated, contact, contributor, controller, conversion, converted, convertible, CTDH, Cut, CycloTM, defect, deficit, Delaware, dental, detain, detected, discharge, disclosing, discourage, discouraged, dispositive, DMF, Dr, Drilling, drying, Eastern, EMEA, employment, enactment, enjoin, enjoy, entitle, exceeded, execute, facilitate, failed, fiduciary, figure, Finally, financing, fincoord, focusing, foregoing, Francisco, Gold, gradually, graduate, greatly, grown, Guide, gynecological, gynecology, harbor, hepatic, Hospital, Hui, impede, indefinitely, Indonesia, influence, inhibit, Internet, Jakarta, joined, jointly, Katarzyna, Kenon, key, Kusmierz, lawsuit, leader, leading, led, liquidation, long, longstanding, losing, low, LP, man, manager, matching, MBA, media, Memorial, merger, Minnesota, misleading, MKT, multitude, NAP, negotiating, nominated, Northwestern, Novit, nutraceutical, NW, NYSE, occasionally, organizational, Ostronic, OTC, OTCQB, Pacific, partnership, Patrick, permanent, person, Pharmacia, pharmacology, Pharmatec, Physiology, planning, Plant, Polpharma, practical, preference, presently, priced, principally, professor, promulgated, proper, proved, pulse, quantity, Quian, Randall, recognition, region, reorganizing, repositioning, resided, restructure, retail, retained, retired, revoked, Russian, San, Scarsdale, School, secretary, seize, send, Shanahan, Sieger, slate, spouse, standing, strategic, strategically, Suite, surgery, Switzerland, symbol, teaching, Tempo, TFBU, thereto, tier, Toig, treasurer, Trust, trustee, understand, unexercised, University, unvested, USP, utilization, validation, ValueAct, vast, vested, vi, vii, visibility, vision, vote, voting, Western, William, wind, work, worth, York, Zurich
Financial reports
10-K
2020 FY
Annual report
12 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
14 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
15 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
Current reports
8-K
Other Events
22 Dec 20
8-K
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
11 Dec 20
8-K
Material Modifications to Rights of Security Holders
10 Nov 20
8-K
Submission of Matters to a Vote of Security Holders
23 Oct 20
8-K
Unregistered Sales of Equity Securities
2 Sep 20
8-K
Entry into a Material Definitive Agreement
6 May 20
8-K
Unregistered Sales of Equity Securities
27 Apr 20
8-K
Submission of Matters to a Vote of Security Holders
27 Aug 19
8-K
Departure of Directors or Certain Officers
14 Jun 19
8-K
Departure of Directors or Certain Officers
7 Jun 19
Registration and prospectus
S-3
Shelf registration
19 Mar 21
424B4
Prospectus supplement with pricing info
11 Dec 20
424B4
Prospectus supplement with pricing info
10 Dec 20
8-A12B
Registration of securities on exchange
8 Dec 20
S-1/A
IPO registration (amended)
3 Dec 20
S-1/A
2020 Q3
IPO registration (amended)
17 Nov 20
S-1/A
2020 Q3
IPO registration (amended)
16 Nov 20
S-1
2020 Q2
IPO registration
29 Sep 20
D
$3M in equity / options, sold $2.83M, 19 investors
3 Sep 20
D
$2M in equity, sold $2M, 51 investors
29 Apr 20
Proxies
DEF 14A
Definitive proxy
15 Sep 20
PRE 14A
Preliminary proxy
3 Sep 20
DEF 14A
Definitive proxy
19 Jul 19
PRE 14A
Preliminary proxy
8 Jul 19
DEF 14A
Definitive proxy
15 Apr 18
PRE 14A
Preliminary proxy
3 Apr 18
DEF 14A
Definitive proxy
3 Nov 04
PRE 14A
Preliminary proxy
18 Oct 04
DEF 14C
Information statement
24 Aug 04
PRE 14C
Preliminary information
7 Jun 04
Other
EFFECT
Notice of effectiveness
9 Dec 20
CORRESP
Correspondence with SEC
3 Dec 20
CORRESP
Correspondence with SEC
3 Dec 20
UPLOAD
Letter from SEC
5 Oct 20
EFFECT
Notice of effectiveness
15 Jul 19
CORRESP
Correspondence with SEC
9 Jul 19
UPLOAD
Letter from SEC
9 Jul 19
UPLOAD
Letter from SEC
16 Sep 13
CORRESP
Correspondence with SEC
2 Sep 13
UPLOAD
Letter from SEC
28 Aug 13
Ownership
4
Cyclo Therapeutics / Francis Patrick Ostronic ownership change
12 Apr 21
4
Cyclo Therapeutics / Markus Sieger ownership change
30 Mar 21
4
Cyclo Therapeutics / Joshua M Fine ownership change
30 Mar 21
4
Cyclo Therapeutics / Sharon Hemond Hrynkow ownership change
30 Mar 21
4
Cyclo Therapeutics / Francis Patrick Ostronic ownership change
30 Mar 21
4
Cyclo Therapeutics / JEFFREY TATE ownership change
30 Mar 21
4
Cyclo Therapeutics / Randall M. Toig ownership change
8 Mar 21
SC 13G/A
Cyclo Therapeutics / HIRSCHMAN ORIN ownership change
11 Feb 21
4
Cyclo Therapeutics / Markus Sieger ownership change
27 Jan 21
4
Cyclo Therapeutics / Michael Eric Lisjak ownership change
25 Jan 21
Reddit threads
Significant Insider Trading Activity (Last 7 Days)
1 Apr 21
The worst thing you can do is sell at a loss
23 Feb 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - February 18, 2021
17 Feb 21
Stocks to Watch 09/02/2021
9 Feb 21
(2/9) Tuesday's Pre-Market Stock Movers & News
9 Feb 21
Morning Update for Tuesday, 02/09/21
9 Feb 21
Trying to Payoff Mortgage before Husband goes on Disability
8 Feb 21
Watchlist 2/5/2021
5 Feb 21
I'm looking to learn about how to create a diversified portfolio after having gambled away 1500$
4 Feb 21
$CYTH: Low-Float 32M Cap vs $SAVA $3B Market Cap
3 Feb 21